Clinical Trial Update: The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing immune response in newly diagnosed glioblastoma patients treated with pembrolizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Medical University of Silesia | Conditions: Newly Diagnosed Glioblastoma | Phase 4 | Status: RECRUITING